Tenon Medical (TNON) Falls -60% Over 30 Days After Reverse Split and Dilution Pressure
Key Takeaways
- Tenon Medical (TNON) shares have fallen roughly 60% over the past 30 days, closing at $2.44 on September 9, 2026, down from $6.14 in early August.
- The move reflects a 1-for-35 reverse stock split, continued share dilution, and a second-quarter earnings miss, only partly offset by the full repayment of convertible notes.
- Nasdaq listing-compliance concerns have dominated sentiment: the company regained both the minimum bid price and stockholders' equity requirements in recent months but remains under significant financial pressure.
- Fundamentals stay strained, with trailing-twelve-month revenue of about $5.3 million against a net loss of roughly $13.7 million and a micro-cap market valuation.
A Closer Look at Tenon Medical (TNON) and Its Position in the Market
Tenon Medical, Inc. develops medical devices aimed at sacroiliac (SI) joint disorders, a frequent cause of lower back pain. Its main offering, the Catamaran SI Joint Fusion System, relies on a single titanium implant inserted via a minimally invasive approach. After acquiring most assets of SiVantage, Inc. and SIMPL Medical, LLC in August 2025, the company added the SImmetry+ SI Joint Fusion System for a lateral-access method.
Based in Los Gatos, California, and founded in 2012, Tenon operates with a modest team in a competitive space that includes larger names such as SI-BONE (SIBN). The stock draws attention for its specialized technology and commercialization efforts, though its micro-cap scale, repeated financing needs, and route to profitability remain key investor focus areas. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Stock Performance: -60% Decline Over the Past 30 Days and an Even Steeper Quarterly Slide
In the last 30 days, TNON has moved sharply lower. On an adjusted basis the stock closed near $6.14 early in August and finished at $2.44 on September 9, 2026, for a decline of approximately 60% — calculated as (2.44 − 6.14) ÷ 6.14 = −60.3%.
The quarterly view shows an even larger drop. Roughly three months earlier, in mid-June, shares traded near $21.60 on a split-adjusted basis, so the stock has lost nearly 89% over the trailing quarter. This extended weakness has occurred amid heavy dilution, ongoing cash burn, and the lengthy process of restoring Nasdaq listing compliance.
Factors Behind the Recent 30-Day Drop in TNON
Multiple elements contributed to the recent weakness. Tenon completed a 1-for-35 reverse stock split on August 10, 2026, intended to push the price above Nasdaq’s $1.00 minimum bid rule. The split restored bid-price compliance, which Nasdaq confirmed on August 24, 2026, yet reverse splits often bring fresh selling, and TNON followed that pattern.
Dilution continued as an ongoing concern, with the company maintaining an at-the-market offering and filing updated registration statements that point to potential additional share sales. On August 13 the company posted a second-quarter earnings miss that highlighted persistent losses despite revenue growth. A modestly positive note came on September 9, 2026, when Tenon announced full repayment of its senior convertible promissory notes, removing convertible-debt overhang from the balance sheet. Shares rose in the next session, though the rebound left the stock far below its level a month earlier. From what I see, the dilution overhang still weighs on sentiment.
Broader Drivers of the Quarterly Performance Decline
The larger quarterly drop stems from a multi-month story rather than one event. Tenon has turned repeatedly to capital markets, including a roughly $4.2 million public offering in July 2026 that helped satisfy Nasdaq’s stockholders’ equity requirement. Each raise has diluted shareholders and pressured the share price.
At the same time, the company has managed a series of Nasdaq deficiency notices, the reverse split, and tightening liquidity. With trailing revenue of about $5.3 million, a gross margin near 67%, and a net loss of roughly $13.7 million, Tenon has not yet shown a clear path to profitability, which keeps investor confidence limited even as its product lineup grows. I also checked this using Tickeron’s AI Trend Prediction Engine to gauge potential momentum shifts.
What to Watch for TNON Stock Going Forward
Investors should track Tenon’s next earnings report, expected in November 2026, for evidence of stronger revenue trends and smaller losses. Cash runway and the pace of further dilution through the at-the-market program will matter given negative free cash flow.
Listing compliance stays relevant: Tenon must keep demonstrating compliance with Nasdaq’s stockholders’ equity requirement in future filings. On the commercial front, progress expanding Catamaran and SImmetry+ adoption, clinician training, and insurance coverage will influence the longer-term outlook. Competitive pressure from larger SI joint fusion companies and wider medical-device sector conditions add more variables. These elements together carry material risk and deserve careful review without assuming recent price drops mark a bottom.
How Tickeron’s AI Trading Bots Support My Research
When analyzing volatile names like TNON, I often turn to Tickeron’s AI Trading Bots for additional perspective. The platform lets me review a range of automated strategies across different timeframes and risk levels, which helps me cross-check my own conclusions against data-driven signals without replacing independent judgment. It is one tool among several I use to stay organized on micro-cap situations.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
TNON sees its 50-day moving average cross bullishly above its 200-day moving average
The 50-day moving average for TNON moved above the 200-day moving average on September 29, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 48 of 61 cases where TNON's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 79%.
The Moving Average Convergence Divergence (MACD) for TNON just turned positive on September 10, 2026. Looking at past instances where TNON's MACD turned positive, the stock continued to rise in 27 of 37 cases over the following month. The odds of a continued upward trend are 73%.
Following a +143.03% 3-day Advance, the price is estimated to grow further. Considering data from situations where TNON advanced for three days, in 131 of 161 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 01, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on TNON as a result. In 74 of 77 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TNON declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for TNON entered a downward trend on September 18, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 1 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 33 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.021) is normal, around the industry mean (10.853). P/E Ratio (0.137) is within average values for comparable stocks, (98.910). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.052). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (0.218) is also within normal values, averaging (39.828).
The Tickeron Price Growth Rating for this company is 95 (best 1 - 100 worst), indicating slightly worse than average price growth. TNON’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TNON’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 96, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry MedicalNursingServices
Advertisement